Paclitaxel trevatide - Angiochem

Drug Profile

Paclitaxel trevatide - Angiochem

Alternative Names: ANG-1005; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem; Paclitaxel-AngioPep1-conjugate-Angiochem

Latest Information Update: 07 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 06 Aug 2018 Angiochem receives Special Protocol Assessment from the US FDA for a phase III trial of paclitaxel trevatide for Carcinomatous meningitis and Brain metastases
  • 02 Aug 2018 Angiochem plans a phase III trial for Brain metastases later in 2018
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top